Clinical trial
A Phase I/IIa Study to Evaluate the Efficacy of DB107-RRV (Formerly Toca511), Administered to Subjects at Time of Resection and Intravenously Thereafter, in Combination With DB107-FC (Formerly Toca FC) and Radiation Therapy or DB107-FC, Temozolomide (TMZ) and Radiation Therapy in Patients With Newly Diagnosed High Grade Glioma
NCT06504381 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIa Study to Evaluate the Efficacy of DB107-RRV (Formerly Toca511), Administered to Subjects at Time of Resection and Intravenously Thereafter, in Combination With DB107-FC (Formerly Toca FC) and Radiation Therapy or DB107-FC, Temozolomide (TMZ) and Radiation Therapy in Patients With Newly Diagnosed High Grade Glioma
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 8, 2025
- Completion date
- January 31, 2042
- Enrollment
- 70 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
high grade glioma, mgmt-methylated glioblastoma, mgmt-unmethylated glioblastoma